Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

NPR | By Yuki Noguchi

Published October 26, 2026 at 2:42 AM MDT

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.

Tags

Morning Edition

Yuki Noguchi

Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C.

The Latest From Boise State Public Radio

Scandalized

In each episode of Scandalized, political scientists Charlie Hunt and Jaci Kettler unpack a political scandal from American history: the story, its scandalous details, the political meaning and motivations behind the act.

Listen to the new season of Scandalized

You make stories like this possible.

The biggest portion of Boise State Public Radio's funding comes from readers like you who value fact-based journalism and trustworthy information.

Your donation today helps make our local reporting free for our entire community.

Donate